Cargando…
Delivery of therapeutic small interfering RNA: The current patent-based landscape
Implementing small interfering RNA (siRNA) is a promising therapy because it silences disease-related genes theoretically. However, the efficient delivery of siRNA is challenging, which limits its therapeutic applications. Various pharmaceutical delivery systems containing key technologies have been...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263868/ https://www.ncbi.nlm.nih.gov/pubmed/35847171 http://dx.doi.org/10.1016/j.omtn.2022.06.011 |
_version_ | 1784742844271951872 |
---|---|
author | Chen, Yu Xiong, Shi-Hang Li, Fei Kong, Xiang-Jun Ouyang, De-Fang Zheng, Ying Yu, Hua Hu, Yuan-Jia |
author_facet | Chen, Yu Xiong, Shi-Hang Li, Fei Kong, Xiang-Jun Ouyang, De-Fang Zheng, Ying Yu, Hua Hu, Yuan-Jia |
author_sort | Chen, Yu |
collection | PubMed |
description | Implementing small interfering RNA (siRNA) is a promising therapy because it silences disease-related genes theoretically. However, the efficient delivery of siRNA is challenging, which limits its therapeutic applications. Various pharmaceutical delivery systems containing key technologies have been developed and patented, which are of great concern to developers in the field. Despite numerous studies devoted to siRNA-delivery technologies, few researchers have systematically examined relevant patents. Patents, as bridges connecting academic progress with applicable innovation, encapsulate cumulative technological innovations and provide valuable information for academic research and commercial development. This study aims to analyze advances in therapeutic siRNA delivery technology from a patent perspective. A total of 11,509 patent documents from 3,309 patent families were collected, classified into 10 technological categories, and comprehensively analyzed. An overall patent landscape of siRNA delivery was presented from the temporal, spatial, organizational, and technological dimensions. This work is expected to help researchers and developers in the field of siRNA delivery form a basis for decision-making by combining our findings with supplementary data. |
format | Online Article Text |
id | pubmed-9263868 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-92638682022-07-14 Delivery of therapeutic small interfering RNA: The current patent-based landscape Chen, Yu Xiong, Shi-Hang Li, Fei Kong, Xiang-Jun Ouyang, De-Fang Zheng, Ying Yu, Hua Hu, Yuan-Jia Mol Ther Nucleic Acids Original Article Implementing small interfering RNA (siRNA) is a promising therapy because it silences disease-related genes theoretically. However, the efficient delivery of siRNA is challenging, which limits its therapeutic applications. Various pharmaceutical delivery systems containing key technologies have been developed and patented, which are of great concern to developers in the field. Despite numerous studies devoted to siRNA-delivery technologies, few researchers have systematically examined relevant patents. Patents, as bridges connecting academic progress with applicable innovation, encapsulate cumulative technological innovations and provide valuable information for academic research and commercial development. This study aims to analyze advances in therapeutic siRNA delivery technology from a patent perspective. A total of 11,509 patent documents from 3,309 patent families were collected, classified into 10 technological categories, and comprehensively analyzed. An overall patent landscape of siRNA delivery was presented from the temporal, spatial, organizational, and technological dimensions. This work is expected to help researchers and developers in the field of siRNA delivery form a basis for decision-making by combining our findings with supplementary data. American Society of Gene & Cell Therapy 2022-06-22 /pmc/articles/PMC9263868/ /pubmed/35847171 http://dx.doi.org/10.1016/j.omtn.2022.06.011 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Chen, Yu Xiong, Shi-Hang Li, Fei Kong, Xiang-Jun Ouyang, De-Fang Zheng, Ying Yu, Hua Hu, Yuan-Jia Delivery of therapeutic small interfering RNA: The current patent-based landscape |
title | Delivery of therapeutic small interfering RNA: The current patent-based landscape |
title_full | Delivery of therapeutic small interfering RNA: The current patent-based landscape |
title_fullStr | Delivery of therapeutic small interfering RNA: The current patent-based landscape |
title_full_unstemmed | Delivery of therapeutic small interfering RNA: The current patent-based landscape |
title_short | Delivery of therapeutic small interfering RNA: The current patent-based landscape |
title_sort | delivery of therapeutic small interfering rna: the current patent-based landscape |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263868/ https://www.ncbi.nlm.nih.gov/pubmed/35847171 http://dx.doi.org/10.1016/j.omtn.2022.06.011 |
work_keys_str_mv | AT chenyu deliveryoftherapeuticsmallinterferingrnathecurrentpatentbasedlandscape AT xiongshihang deliveryoftherapeuticsmallinterferingrnathecurrentpatentbasedlandscape AT lifei deliveryoftherapeuticsmallinterferingrnathecurrentpatentbasedlandscape AT kongxiangjun deliveryoftherapeuticsmallinterferingrnathecurrentpatentbasedlandscape AT ouyangdefang deliveryoftherapeuticsmallinterferingrnathecurrentpatentbasedlandscape AT zhengying deliveryoftherapeuticsmallinterferingrnathecurrentpatentbasedlandscape AT yuhua deliveryoftherapeuticsmallinterferingrnathecurrentpatentbasedlandscape AT huyuanjia deliveryoftherapeuticsmallinterferingrnathecurrentpatentbasedlandscape |